Connect with us


Connecticut Board of Physicians Adds Chronic Pain to Qualifying Cannabis Medical Conditions List



Connecticut Board of Physicians Adds Chronic Pain to Qualifying Cannabis Medical Conditions List
  • Connecticut’s current medical marijuana program includes 36 qualifying conditions.
  • The state is considering the legalization of recreational marijuana, following a meeting with the governor of New York.

While there are already 30+ states that have approved the use of marijuana for medical purposes, the only way that consumers are able to obtain the substance is by having one of the qualifying conditions. Considering that cannabis is known for helping to relieve pain, the Connecticut Board of Physicians recently approved both chronic pain and Ehlers-Danlos syndrome to be added to their medical cannabis program in the state. According to the Mayo Clinic, Ehlers-Danlos syndrome is a condition that affects the connective tissues in the body.

Before these conditions can be added to the list of qualifying conditions, the Regulations Review Committee of the state General Assembly must first approve the notion. Interstitial cystitis, a syndrome that causes chronic bladder pain, was recently approved by the state Department of Consumer Protection. Other conditions approved by the state department include:

  • Intractable neuropathic pain, as long as traditional medical treatments do not soothe it
  • Medial arcuate ligament syndrome, which causes the patient to experience severe abdominal pain
  • Tourette syndrome
  • Vulvodynia and vulvar burning, imposing continual pain in female genitalia

If the General Assembly chooses to approve the two conditions, there will be a total of 38 conditions that qualify for the state’s medical marijuana program. As of September 29th, only four producers exist in the medical marijuana industry, supplying 14 dispensaries and 36,653 patients. There are 1,117 physicians qualified to recommend and prescribe medical marijuana at this time.

Night terrors/parasomnia was also presented to the Connecticut Board of Physicians as a potential qualifying condition for medical marijuana use. However, it did not gain the approval of the board.

As the environment surrounding marijuana evolves, lawmakers in Connecticut are considering the legalization of recreational marijuana as well. Governor Ned Lamont and New York’s Governor Andrew Cuomo spoke about the possibility of legalization, and the need to impose regulations that allow consumers to seamlessly move between the states without confusion. The two states share borders with Massachusetts, which approved recreational marijuana sales in 2018.

Michael is a freelance writer with several years of experience in writing of all kinds. From the uber-technical to the more relaxed, he is well-versed in a variety of styles. Lately, his work has been primarily focused on the CBD industry—a market with which he has a particular background and interest. Michael has an extensive interest and experience in legal research for the CBD market, and he has a knack for well-researched pieces and guides for the growing CBD and medicinal cannabis community.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.